PennyPerformers.com: "Penny Stocks that Perform" picks are: CYTR, EDWY, SPNG, UNDT

Jun 25, 2009 (M2 PRESSWIRE via COMTEX) -- UNDT | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: CytRx Corporation (NASDAQ: CYTR), eDOORWAYS (PINKSHEETS: EDWY), SpongeTech(R) Delivery Systems, Inc. (OTCBB: SPNG), Universal Detection Technology (OTCBB: UNDT)

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Jun 25, 2009 -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that an experimental animal trial produced statistically significant evidence that the company's chaperone amplifying drug candidate arimoclomol provided protection from the detrimental cognitive and sensorimotor effects of low atmospheric oxygen (hypoxia) that occurs at high altitudes. Data from this trial will be presented in a poster, "A heat-shock protein co-inducer treatment improves behavioral performance in rats exposed to hypoxia," on July 9 at the 37th Annual International Society on Oxygen Transport to Tissue (ISOTT) Conference, being held in Cleveland, Ohio.

"The ability to help people adapt more readily and rapidly to extreme environmental conditions, such as high altitude, without loss of cognitive function has a number of important applications. This is particularly important to those who travel to high altitudes to accomplish tasks and require the maintenance of good judgment and rational thinking that is usually lost during the adjustment period," said Steven Kriegsman, CytRx President and CEO. "Importantly, we believe these animal data provide indirect added support for arimoclomol as a potential treatment for stroke recovery, since damage during stroke is caused by a lack of oxygen, and are yet another example of arimoclomol's broad therapeutic potential and its value as a possible partnership candidate."

The brain is physiologically vulnerable to hypoxia due to its high demand for oxygen. Accordingly, hypobaric hypoxia (high altitude exposure) results in stress-related damage to the brain and leads to impaired behavioral performance. This can often lead to tragic results as highlighted by the recent and widely reported death of climber Frank Ziebarth, 29, who reached the summit of Mount Everest without the use of supplemental oxygen, but was exhausted and confused, and ultimately perished during his descent due to lack of oxygen.

The trial was conducted under the supervision of Joseph C. LaManna, Ph.D., chairman of the Anatomy Department and Professor in the Neurology, Physiology/Biophysics and Neuroscience departments at the Case Western Reserve University School of Medicine (Cleveland, Ohio). Twenty-four rats were randomly assigned to four drug- and vehicle-treated groups (six rats per group) and exposed to either normal atmospheric oxygen or hypobaric hypoxia for 10 days. Drug-treated rats were administered intraperitoneal (abdominal) injections of arimoclomol daily, while control rats were given only the solution in which arimoclomol was dissolved. Hypoxic rats were kept in hypobaric chambers at a constant pressure equivalent to one-half of sea level (0.5 atmospheres), with the exception of approximately three hours daily in which they were returned to normal atmospheric pressure for behavioral tests. Normoxic rats were housed in the same room to ensure identical ambient conditions. Tissues from all trial rats were valuated for markers of hypoxic damage.

Trial data indicated that arimoclomol improved both cognitive and motor performance during the adaptation to simulated high-altitude exposure. These results included improved ability to explore a maze, and ability to recognize and explore a novel object, which was evaluated through memory tests. In addition, signs of programmed cell death, or apoptosis, in the brain during hypoxic exposure were diminished and hypoxia-induced inflammatory responses were also suppressed by arimoclomol.

About Arimoclomol

Arimoclomol, a molecular chaperone regulator drug candidate, is being considered as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and stroke recovery. Arimoclomol has been studied in seven Phase 1 and two Phase 2 clinical trials without any significant adverse events. CytRx's Phase 2b clinical trial with arimoclomol as a treatment for ALS was placed on clinical hold by the FDA in January 2008, unrelated to any data generated by human studies, and CytRx expects to submit this quarter to the FDA data from additional preclinical toxicology studies to potentially resolve this issue. The Company anticipates a response from the FDA in the third quarter. In February 2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial to study arimoclomol in a subset of patients with the inherited or familial form of ALS or Lou Gehrig's disease.

About Molecular Chaperone Regulation

CytRx is a leader in molecular chaperone regulation technology. The Company currently has two orally administered, clinical-stage drug candidates and recently discovered a series of additional compounds that may provide a pipeline for additional drug candidates. The Company's drug candidates are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of "molecular chaperones." Because damaged proteins are thought to play a role in many diseases, activation of molecular chaperones that help to reduce the accumulation of misfolded proteins may have therapeutic efficacy in a broad range of disease states. Similarly, CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII).

Jun 24, 2009 -- eDOORWAYS (PINKSHEETS: EDWY), which is expected to launch its highly anticipated Consumer 3.0(SM) platform in 2009, seems to have become a global curiosity according to people close to the company. This growing interest has translated into an international investment opportunity for those abroad. It is partly for this reason eDOORWAYS is taking the show worldwide -- now offering the company's 2nd shareholder conference call through live streaming media technology, in addition to an international dial-in number.

"The fact is, we have loyal shareholders all over the World," says Gary Kimmons, Chairman & CEO of eDOORWAYS. "We intend to reach them."

Initially, in an attempt to appease foreign investors, eDOORWAYS added an international dial-in number for this call; something it had not done on its last conference call. With increased traffic in "info request" emails, calls to the company and corporate blog communications signifying genuine interest, it was quickly determined that access to the 2nd conference call had to be widely broadened. The decision to stream a live webcast to ensure not only domestic reach, but more so international interest was validated when blog communications from shareholders overseas expressed disappointment at the possibility of their exclusion from this event.

"People across the globe are becoming shareholders in eDOORWAYS," stated Kimmons. "They are showing interest and supporting our efforts because like Americans, 'they get it!' It seems like people everywhere are truly beginning to understand we're not simply a concept. Our platform, which is designed to fully leverage the capabilities of emerging Web 3.0 technology, is the amalgamation of various interconnected courses of action taken over a period of several intense years. Frankly, it's been a long time coming. So why should our shareholders be limited to a few phone lines and audio replay! We want the entire world to have the opportunity, in real time, to receive the news they have all been waiting for."

Excitement in and around the company has kicked into high gear as the call date nears. While no details have been provided as to official contents of the presentation, people close to the company suggest that both Gary Kimmons and Kristen Claflin, the company's newly appointed Brand Marketing and Site Monetization Strategist, are revved up and ready to address callers. It's also been suggested that there could be the possibility of one or two unexpected surprises that may capture the attention of new investors.

The domestic and international dial-in numbers, as well as a link to the webcast, will be released tomorrow, Friday, June 26th, 2009. This information will also be presented on both the company's corporate website and blog.

Jun 24, 2009 -- SpongeTech(R) Delivery Systems, Inc., America's Cleaning Company(TM), (OTCBB: SPNG | Quote | Chart | News | PowerRating) is pleased to announce that the Company has secured approximately $7.25 million in new orders, bringing the total to approximately $13.65 million of purchase orders for the month of June to date. The newly reported orders include SpongeTech(R) receiving an initial purchase order with a new major retailer in Canada. SpongeTech(R)'s products are being ordered by various retail outlets all through North America including drugstores, supermarkets, membership warehouse clubs, and big box stores. The Company continues to brand itself as America's Cleaning Company(TM).

"We are excited to report what appears to be a record month for the Company so far," comments SpongeTech(R)'s COO, Steven Moskowitz. "We are proud to introduce our product line to our neighbors up north!! Establishing this new retailer will now provide our Company with an impressive launch of our products to the consumers in Canada." Moskowitz continues, "We have begun shipping our newest children's bath sponge product to the many retailers who have pre-ordered the product and we expect to see it in those stores soon."

About SpongeTech(R) Delivery Systems, Inc.

SpongeTech(R) Delivery Systems is a company which designs, produces, and markets unique lines of reusable cleaning products for Car Care, Child Care, Home Care and Pet Care usages. These sponge-like products utilize SpongeTech(R)'s proprietary, patent (and patent-pending) technologies and other technologies involving hydrophilic (liquid absorbing) foam, polyurethane matrices or other ingredients. The Company's sponge-like products are pre-loaded with specially formulated ingredients such as soap, conditioner and/or wax that are released when the sponge is soaked and applied to a surface with minimal pressure. SpongeTech(R) is currently exploring additional applications for its technology in the health, beauty, and medical markets. SpongeTech(R) Delivery Systems, Inc. intends to globally brand its Company as America's Cleaning Company(TM) .

Jun 24, 2009 -- Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today that it has been awarded a North Atlantic Treaty Organization (NATO) CAGE Number for its biological weapon detection systems. The CAGE code allows for marketing of the instruments to NATO affiliated countries.

The NATO Commercial and Government Entity, or NCAGE, code is a five-character ID number that identifies government contractors. NCAGE codes are an important part for companies winning contracts with NATO affiliated countries. The UDT CAGE/NCAGE code is: 1WLU0. UNDT is now listed along with all U.S. and NATO companies with a CAGE/NCAGE Code. The code lists UNDT in a primary vendor database for the U.S. Federal Government and is used as a government tool for the Department of Homeland Security, Department of Defense, NATO and NASA Agencies. Having this information immediately available allows the U.S. Government and NATO countries to rapidly find the companies with the right capabilities to offer services for required government initiatives, including research & development projects, particular supply needs, up to a pandemic alert requirement or other emergency requirements.

"The awarding of our NCAGE code is a significant step for us to market our equipment to a rapidly expanding NATO alliance that has significant biological weapon detection needs," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

For More Information Regarding Penny Performers, Contact Jason A. Hilton at: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com

CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com PennyPerformers.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index